NEI Research News

Using a new stem-cell based model made from skin cells, scientists found the first direct evidence that Stargardt-related ABCA4 gene mutations affect a layer of cells in the eye called the retinal pigment epithelium (RPE).

Study from UT Southwestern Medical Center could lead to new treatments for deadly childhood eye cancer.

Fulya Yaylacıoğlu Tuncay, M.D., Ph.D., said she gained crucial experience in translational medicine as the first participant in an ocular genetics fellowship program sponsored by NEI and the International Council of Ophthalmology.

Researchers at the National Eye Institute (NEI) have shown for the first time how cells across different tissue layers in the eye are affected in people with choroideremia, a rare genetic disorder that leads to blindness.

Researchers from the National Eye Institute (NEI) have developed a gene therapy that rescues cilia defects in retinal cells affected by a type of Leber congenital amaurosis (LCA), a disease that causes blindness in early childhood.

The patient received the therapy as part of a clinical trial that is the first in the United States to use replacement tissues from patient-derived induced pluripotent stem cells.

Three scientific teams that developed physiologically competent retinal organoid systems have won the final phase of the 3D Retinal Organoid Challenge (3D ROC).

Using a new imaging technique, researchers from the National Eye Institute have determined that retinal lesions from vitelliform macular dystrophy (VMD) vary by gene mutation.

NEI researcher Mitra Farnoodian Tedrick, Ph.D., received a $65,000 grant from the Knights Templar Eye Foundation (KTEF) to identify drugs to treat a rare blinding condition called Stargardt disease.

A new report outlines progress toward the National Eye Institute's Audacious Goals Initiative (AGI), an effort to restore vision through research in regenerative medicine. The report, published in Nature Medicine.